- Pembrolizumab in therapy of metastatic melanoma2016 | Publication without faculty affiliation
- Pembrolizumab in pretreated patient2018 | Faculty of Medicine in Hradec Králové
- Pembrolizumab in the treatment of non-small-cell lung cancer2016 | Publication without faculty affiliation
- Pembrolizumab - indication overview2019 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Pembrolizumab in combination with radiotherapy in a patient with generalized melanoma2020 | First Faculty of Medicine
- First-line pembrolizumab for metastatic non-small-cell lung cancer2020 | First Faculty of Medicine
- A long-term survivor female patient with metastatic melanoma after treatment with pembrolizumab in the third line2020 | First Faculty of Medicine
- Pembrolizumab - another successfull therapy in the treatment of melanoma2016 | Third Faculty of Medicine
- Complete response to pembrolizumab in a patient with stage IV NSCLC (non-small cell lung cancer)2020 | First Faculty of Medicine
- Monotherapy with pembrolizumab in the first-line treatment of non-small cell lung cancer with a high expression of PD-L1 >= 50 %2020 | Faculty of Medicine in Pilsen
- Pembrolizumab: treatment in patients with axial skeletal metastases, after stabilization of the spine – case reports2023 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Treatment with pembrolizumab in a patient with non-small cell lung cancer after a faecal transplantation - case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Case report of a patient with generalized NSCLC with high PD-L1 expression treated with pembrolizumab2020 | Publication without faculty affiliation
- Pembrolizumab as a first-line therapy in spinocellular esophageal cancer2021 | First Faculty of Medicine
- Pembrolizumab v 1. linii léčby NSCLC2018 | Second Faculty of Medicine
- Pembrolizumab v terapii slizničního melanomu2016 | First Faculty of Medicine
- Pacientka s NSCLC léčeným ve druhé linii pembrolizumabemi2017 | Publication without faculty affiliation
- Pembrolizumab plus enfortumab vedotin in urothelial cancer2024 | Faculty of Medicine in Pilsen
- Pembrolizumab v léčbě nemalobuněčného plicního karcinomu2019 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. MK 3475-062Publication without faculty affiliation
- Adjuvant therapy for melanoma in real world2023 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial2023 | First Faculty of Medicine
- NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy2021 | First Faculty of Medicine
- Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study2023 | First Faculty of Medicine
- Výborná odpověď na léčbu pembrolizumabem u nemocné se 100% expresí PD-L12019 | Third Faculty of Medicine
- Výrazná regrese nemalobuněčného plicního tumoru po třech cyklech pembrolizumabu2019 | Third Faculty of Medicine
- Immunooncologic therapy of lung cancer. Present and perspectives2020 | Faculty of Medicine in Pilsen
- Pembrolizumab v první linii léčby nemalobuněčného karcinomu plic - kazuistiky2018 | First Faculty of Medicine
- Editorial2017 | Faculty of Medicine in Pilsen
- Pembrolizumab v první linii léčby nemalobuněčného karcinomu plic2018 | Second Faculty of Medicine